biOracle
Bringing Preventive Care to Life

 

Search Our site
Search Our site
 

Latest Company News...

Visit us at Medica 2009, 18 -21 November, Hall 16, Stand F04-7... 

>> Read Latest biOracle News Here

 

Why Treat when you can Prevent ?

   Home | About Us | Products | Opportunities | News | Contact Us | Location

Our Products and Development Pipeline

Since its formation, biOracle has primarily been concerned with completing development of its early products. Commercialisation of these products started early in 2005, with launches scheduled to take place over the next couple of years.

Canditect, our rapid point of care diagnostic test for vaginal candidiasis (candida overgrowth sometimes known as thrush), is already available in a number of countries, where it is well-received by gynaecologists, physicians and patients alike. Clinical evaluation of Canditect demonstrates that it is more effective in the diagnosis of thrush (vaginitis) than microscopic examination and culture, currently the two most widely used diagnostic techniques.

Further information on each product is available by following the links below.

 

Canditect - a unique point-of-care diagnostic test for candida infections causing thrush

Appytest - a novel point-of-care diagnostic test for appendicitis

biO1039 - a unique point-of-care diagnostic test for bacterial vaginosis

biO1042 - a rapid diagnostic test to measure an important new marker of cardiovascular disease

 

In addition to these products, biOracle is exploring a number of other opportunities in the preventive care arena. 

 

 

 

 

 

 

 

 


biO1039 - a unique point-of-care diagnostic test for bacterial vaginosis

Bacterial vaginosis (BV) is a serious infection caused by an overgrowth of anaerobic bacteria. It is one of the most common reasons for attendance at a Genito-Urinary Medicine Clinic, and may be found in up to 10% of the female population.

Although many people may experience no symptoms from bacterial vaginosis, it is associated with complications in pregnancy, pelvic inflammatory disease and transmission of other more serious infections.

Currently, diagnosis of bacterial vaginosis is most frequently carried out by physical examination and laboratory testing, a process that can be both time-consuming and uncomfortable for the patient.

Introduction of  biOracle's point-of-care diagnostic test for bacterial vaginosis will mean that for the first time clinicians will be able to detect BV and initiate treatment on a single patient visit.

Similarly, after a course of treatment, biOracle's test can be used to demonstrate that the medication has done its job, giving reassurance that the patient is free of the long term consequences associated with this infection.

biO1042 - a rapid diagnostic test to detect an important new marker of cardiovascular disease

Further details to be released as biOracle's clinical programme progresses.

 

 

 

© Copyright 2009 BiOracle Limited. All Rights Reserved